Inaktiver Wert

Andere Sprachen Cytori Therapeutics Inc Nasdaq

Aktien

US23283K2042

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

Plus Therapeutics : Nuclear Medicine and Neurooncology (NMN) Symposium 2024	29.04.
Plus Therapeutics Gets $3 Million Funding Recommendation From Department of Defense	22.04.
Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense	22.04.
Plus Therapeutics, Inc. Receives $3 Million Award Recommendation from the United States Department of Defense	22.04.
Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus’ Management Team	09.04.
Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference	27.03.
Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic	25.03.
Plus Therapeutics, Inc. Announces Validation & Clinical Implementation of Csf-01 Leptomeningeal Cancer Cell Diagnostic	25.03.
Plus Therapeutics : March 2024 Corporate Presentation	13.03.
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases	11.03.
Plus Therapeutics Completes Dosing in Cohort 5 of ReSPECT-LM Phase 1 Trial of Rhenium Obisbemeda in Leptomeningeal Metastases	11.03.
Plus Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights	05.03.
Plus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
North American Morning Briefing : S&P 500 Futures -2-	05.03.
Plus Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on March 5, 2024	27.02.
Plus Updates Financial and Cash Guidance for 2024	18.12.
Plus Therapeutics Partners With K2bio for Development of Novel Tests for Cerebrospinal Fluid (CSF) Tumor Cell and Molecular Biomarker Analyses	12.12.
Plus Therapeutics to Present at the 5th Targeted Radiopharmaceuticals Summit Europe	29.11.
Plus Therapeutics Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting and will Host Key Opinion Leader Webinar	20.11.
Plus Therapeutics, Inc. Reports New Interim ReSPECT-GBM Phase 2 Trial Data at the Society for NeuroOncology Annual Meeting	20.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cytori Therapeutics Inc Nasdaq

Aktien

US23283K2042

Andere Sprachen

Filter